Metabolism and Target Organ Damage Achieves a Higher CiteScore of 3.4!

We are pleased to share that the CiteScore™ 2024 for Metabolism and Target Organ Damage (M&TOD) has risen to 3.4, up from 3.0 in 2023!

This improvement reflects the journal’s growing academic influence and the rising quality of its published research. According to the latest Scopus rankings, M&TOD is now ranked 145th out of 247 journals in the Endocrinology, Diabetes and Metabolism category placing it in the 41st percentile (Q3) - a noteworthy achievement for a young journal launched in late 2021.

This positive momentum underscores the collective dedication and contributions of our authors, Editorial Board members, and peer reviewers. We extend our sincere gratitude to everyone who has supported the journal’s development and helped establish M&TOD as a trusted source of high-quality research on metabolism and target organ damage.M&TOD publishes innovative studies across a wide range of topics, including obesity, diabetes, dyslipidemia, hypertension, and hyperuricemia, focusing on their effects on major target organs such as the liver, heart, kidneys, and brain. Our mission is to advance scientific understanding and improve patient outcomes through rigorous, clinically relevant research.

We sincerely welcome continued support from researchers and clinicians worldwide - as contributors, reviewers, and readers - and look forward to achieving even greater milestones together in the future!

Editor: Alani Luo
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Metabolism and Target Organ Damage